Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Radiopharm Theranostics Limited Sponsored ADR ( (RADX) ).
Radiopharm Theranostics Limited announced an Extraordinary General Meeting scheduled for December 3, 2025, to discuss several key resolutions, including the ratification of prior issued shares and approval for new share issuances. These resolutions, if passed, could significantly impact the company’s capital structure and provide additional resources for its ongoing projects. The meeting will be held both in person and virtually, allowing shareholders to participate and vote on these critical decisions.
The most recent analyst rating on (RADX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited Sponsored ADR stock, see the RADX Stock Forecast page.
More about Radiopharm Theranostics Limited Sponsored ADR
Radiopharm Theranostics Limited operates in the biotechnology industry, focusing on the development and commercialization of radiopharmaceutical products for diagnostic and therapeutic purposes. The company is primarily engaged in creating innovative solutions for cancer treatment and diagnosis, leveraging its expertise in theranostics, which combines therapy and diagnostics.
Average Trading Volume: 35,048
Technical Sentiment Signal: Buy
Current Market Cap: $45.39M
Learn more about RADX stock on TipRanks’ Stock Analysis page.